US Stock MarketDetailed Quotes
TCRT Alaunos Therapeutics
- 1.9600
- -0.0600-2.97%
Close Dec 20 16:00 ET
- 1.9600
- 0.00000.00%
Post 20:01 ET
3.14MMarket Cap-0.27P/E (TTM)
2.0400High1.9500Low9.70KVolume2.0200Open2.0200Pre Close19.21KTurnover0.67%Turnover RatioLossP/E (Static)1.60MShares32.850052wk High1.15P/B2.83MFloat Cap1.630052wk Low--Dividend TTM1.44MShs Float36000.0000Historical High--Div YieldTTM4.46%Amplitude1.6300Historical Low1.9800Avg Price1Lot Size
Alaunos Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 87.75%-781K | 75.99%-1.68M | 79.57%-1.92M | -3.11%-30.14M | -3.58%-7.39M | -3.73%-6.37M | 14.47%-7M | -20.73%-9.38M | 52.44%-29.23M | 52.86%-7.13M |
| Net income from continuing operations | 86.70%-1.13M | 87.14%-1.13M | 83.26%-1.68M | 6.86%-35.14M | 14.37%-7.84M | 4.24%-8.48M | 11.67%-8.77M | -2.66%-10.05M | 52.09%-37.73M | 22.34%-9.16M |
| Operating gains losses | ---- | ---- | ---- | 0.00%7K | ---5K | --2K | ---- | ---- | --7K | ---- |
| Depreciation and amortization | --0 | -99.86%1K | -99.71%2K | -16.09%2.32M | -65.27%241K | -1.74%679K | 2.04%699K | 1.02%696K | 6.24%2.76M | -1.56%694K |
| Other non cash items | ---- | ---- | ---- | -0.52%1.33M | 25.39%-1.1M | 13.57%385K | -30.33%1.46M | 54.76%585K | 4,203.23%1.33M | -457.52%-1.47M |
| Change In working capital | 137.95%266K | 49.85%-656K | 73.16%-409K | -818.85%-6.25M | -241.42%-2.72M | -180.76%-701K | 35.25%-1.31M | -1,655.10%-1.52M | -72.30%870K | 131.51%1.92M |
| -Change in receivables | 0.00%4K | 25.00%-3K | --0 | -99.73%3K | -100.03%-1K | 100.14%4K | ---4K | -99.64%4K | -68.86%1.11M | 626.75%2.91M |
| -Change in prepaid assets | 173.66%344K | -195.81%-320K | 526.53%307K | -256.52%-1.36M | -2,646.00%-1.27M | -193.21%-467K | 100.00%334K | -67.11%49K | -90.56%867K | -96.76%50K |
| -Change in payables and accrued expense | 76.23%-82K | 40.64%-333K | 50.42%-716K | -587.16%-4.76M | 14.89%-2.41M | -110.14%-345K | -96.84%-561K | -47.80%-1.44M | 93.23%-693K | 62.57%-2.83M |
| -Change in other current assets | ---- | ---- | ---- | 281.68%500K | ---- | ---- | ---- | ---- | -34.83%131K | --0 |
| -Change in other current liabilities | --0 | --0 | --0 | -17.71%-638K | -74.18%465K | 185.60%107K | 46.89%-1.08M | 30.00%-133K | -224.88%-542K | 1,159.41%1.8M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 87.75%-781K | 75.99%-1.68M | 79.57%-1.92M | -3.11%-30.14M | -3.58%-7.39M | -3.73%-6.37M | 14.47%-7M | -20.73%-9.38M | 52.44%-29.23M | 52.86%-7.13M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | 797.41%1.35M | 1,716.13%1.5M | 107.14%1K | -136.84%-135K | 20.69%-23K | 94.19%-193K | 74.09%-93K |
| Net PPE purchase and sale | --0 | --0 | --0 | 797.41%1.35M | 1,716.13%1.5M | 107.14%1K | -136.84%-135K | 20.69%-23K | 94.19%-193K | 74.09%-93K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | 797.41%1.35M | 1,716.13%1.5M | 107.14%1K | -136.84%-135K | 20.69%-23K | 94.19%-193K | 74.09%-93K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 0 | 0 | -384.88%-18.14M | 0 | 0 | -11.98M | -6.16M | -75.30%6.37M | 4,655.91%8.47M |
| Net issuance payments of debt | --0 | --0 | --0 | -117.27%-18.11M | --0 | --0 | ---11.86M | ---6.25M | -133.33%-8.33M | ---6.25M |
| Net common stock issuance | --0 | --0 | --0 | -99.37%92K | --0 | --0 | --0 | --92K | --14.68M | --14.72M |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -97.97%21K | --0 |
| Net other financing activities | ---- | ---- | ---- | ---125K | --0 | --0 | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | --0 | --0 | -384.88%-18.14M | --0 | --0 | ---11.98M | ---6.16M | -75.30%6.37M | 4,655.91%8.47M |
| Net cash flow | ||||||||||
| Beginning cash position | -86.55%2.46M | -88.93%4.15M | -88.56%6.06M | -30.32%53M | -76.92%11.94M | -69.48%18.32M | -45.16%37.43M | -30.32%53M | -33.91%76.05M | -43.59%51.75M |
| Current changes in cash | 87.75%-781K | 91.21%-1.68M | 87.68%-1.92M | -103.55%-46.93M | -570.18%-5.88M | 22.90%-6.37M | -131.89%-19.12M | -99.54%-15.56M | 40.90%-23.06M | 107.98%1.25M |
| End cash Position | -85.91%1.68M | -86.55%2.46M | -88.93%4.15M | -88.56%6.06M | -88.56%6.06M | -76.92%11.94M | -69.48%18.32M | -45.16%37.43M | -30.32%53M | -30.32%53M |
| Free cash flow | 87.75%-781K | 76.45%-1.68M | 79.70%-1.92M | -3.03%-30.34M | -1.92%-7.39M | -3.51%-6.38M | 13.43%-7.14M | -21.07%-9.44M | 54.55%-29.45M | 53.21%-7.25M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data